VRTX Jan 2024 135.000 call
| Previous close | 103.40 |
| Open | 103.40 |
| Bid | 101.50 |
| Ask | 111.00 |
| Strike | 135.00 |
| Expiry date | 2024-01-19 |
| Day's range | 103.40 - 103.40 |
| Contract range | N/A |
| Volume | |
| Open interest | 1 |
Motley FoolThis Newly Discovered Risk Could Be a Big Headache for Vertex Pharmaceuticals and CRISPR Therapeutics
In the gene editing therapies space, there aren't any competitors being watched more closely than Vertex Pharmaceuticals (NASDAQ: VRTX) and CRISPR Therapeutics (NASDAQ: CRSP). The pair scored regulatory approval in the U.K. on Nov. 16 to market their first gene therapy developed in collaboration and investors have high hopes for a positive commercialization decision by the Food and Drug Administration (FDA) in the U.S. on Friday, Dec. 8. The gene therapy candidate made by Vertex and CRISPR Therapeutics is called exa-cel, and it's intended to treat sickle cell disease (SCD), a hereditary blood disorder that causes red blood cells to have a shape that's closer to a waxing crescent moon than their proper and iconic frisbee-like form.
Motley Fool5 Unstoppable Trends to Invest $1,000 in for 2024
These next-big-thing trends represent some of the most exciting moneymaking opportunities for investors next year.
ZacksWhy Is Vertex (VRTX) Down 6.4% Since Last Earnings Report?
Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
